Getinge announces results from SEMPER FI pilot study of intra-aortic balloon pump showing numerical trend toward reduced mortality in patients with extensive myocardial infarction and persistent ischemia

Food and Healthcare Press Releases Monday May 28, 2018 12:29
WAYNE, New Jersey--28 May--PRNewswire/InfoQuest
Study results presented at EuroPCR 2018

Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study. The study evaluated the use of an intra-aortic balloon pump (IABP) in patients with extensive myocardial infarction (MI, or heart attack) complicated by persistent ischemia (inadequate blood flow) following primary percutaneous coronary intervention (PCI) – a phenomenon called no-reflow. This small pilot study showed positive trends with IABP in reduction of the primary endpoint (a composite endpoint of mortality, necessity for mechanical support due to hemodynamic deterioration, such as left ventricular assist device [LVAD], and hospital readmission for congestive heart failure at six months). Results were presented yesterday in the hotline coronary interventions oral session at the EuroPCR 2018 Congress in Paris by SEMPER FI co-principal investigator Lokien X. van Nunen, M.D., of Catharina Hospital in Eindhoven, The Netherlands.

Patients with large acute MI and signs of persistent ischemia after successful stenting have a poor prognosis and are likely to develop heart failure in the future. An estimated 30 percent of patients with ST elevated MI (STEMI) continue to have persistent ischemia even after the primary culprit artery is opened.i,ii

"Determining which STEMI patients will benefit from IABP has been difficult because of varying results from retrospective and prospective studies," said Dr. van Nunen. "We are encouraged by the results of the SEMPER FI pilot study, which showed a strong signal that IABP may be beneficial in patients with extensive acute MI who continue to experience ischemia even after stenting. We expect that these results will bear out in a trial adequately powered to demonstrate a statistically significant reduction in the composite endpoint if this trend were to continue."

SEMPER FI Study Design and Results

The prospective, randomized, comparative, single-center SEMPER FI pilot study evaluated the use of IABP in patients with extensive MI complicated by persistent ischemia after PCI. The study included 100 patients ages 18 to 75 years with acute STEMI (characterized by summed ST-segment deviation of ≥15 mmHg) and insufficient ST-segment resolution on an ECG 10 to 30 minutes after PCI (stenting) in the catheterization laboratory. Study participants were randomized to IABP for 12 to 24 hours or no IABP according to guidelines to alleviate persisting ischemia. All were followed up for six months.

Results of this pilot study of 100 patients who presented with large acute MI showed a trend toward decreased mortality, LVAD use and hospital readmission for heart failure within six months with use of IABP. Among the IABP group, 2 percent (one patient) experienced the primary endpoint versus 8 percent (four patients) in the non-IABP group (p=0.16).

"The trend toward a mortality benefit with the use of IABP observed in the SEMPER FI pilot study is encouraging because the study was well controlled and did not allow crossover from the conventionally-treated group to IABP, which could have confounded the results," said Dr. Claudius Diez, Chief Medical Officer, Acute Care Therapies, Getinge. "This pilot study is a testament to Getinge's commitment to support clinical research to increase the body of knowledge for our life-saving therapies."

About IABP Therapy

Based on extensive literature supporting the hemodynamic effects and safety and effectiveness of intra-aortic balloon counterpulsation (IABC), the U.S. Food and Drug Administration (FDA) has cleared balloon pumps for use in patients with acute coronary syndrome, patients undergoing cardiac and non-cardiac surgery, and patients experiencing complications of heart failure of both ischemic and non-ischemic etiologies.iii The FDA clearance for these indications was based on results from a comprehensive literature review of IABC devices, which demonstrated low overall rates of complications despite the fact that patients in whom an IAB was implanted had more severe comorbidities and underlying illnesses than patients without a device. Additionally, the literature shows a trend toward fewer device-related complications over time, as balloon catheter sizes have decreased and procedural techniques have improved in recent years.

About Getinge

Getinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the every-day life for people, today and tomorrow.

i Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interven Cardiol. 2010;23:429-436.

ii van Nunen LX, van't Veer M, Schampaert S, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction: old and emerging indications. Neth Heart J. 2013;21:554-560.
iii FDA Executive Summary https://www.federalregister.gov/documents/2013/12/30/2013-31218/cardiovascular-devices-reclassification-of-intra-aortic-balloon-and-control-systems-for-acute .
Logo - https://mma.prnewswire.com/media/322743/Getinge___Logo.jpg

Latest Press Release

Walgreens Boots Alliance and Microsoft establish strategic partnership to transform health care delivery

- Companies aim to improve health outcomes and lower overall costs with enhanced digital and retail experiences and an R&D commitment to build health care solutions through seven-year agreement Walgreens Boots Alliance Inc. (WBA) and Microsoft Corp....

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems. (Logo:...

MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's...

Gift of Life Donor Program is U.S. Leader in Saving Lives

For the 11th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs. Gift of Life broke two national records in 2018,...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today...

Related Topics